Valbiotis SA
PAR:ALVAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Valbiotis SA
Other Current Assets
Valbiotis SA
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Valbiotis SA
PAR:ALVAL
|
Other Current Assets
€158k
|
CAGR 3-Years
-14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Other Current Assets
€34.8m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
1%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other Current Assets
€2.9m
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
|
|
Inventiva SA
PAR:IVA
|
Other Current Assets
€2.9m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Other Current Assets
$2.6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
|
Abivax SA
PAR:ABVX
|
Other Current Assets
€3.2m
|
CAGR 3-Years
52%
|
CAGR 5-Years
58%
|
CAGR 10-Years
39%
|
|
Valbiotis SA
Glance View
Valbiotis SA develops products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
See Also
What is Valbiotis SA's Other Current Assets?
Other Current Assets
158k
EUR
Based on the financial report for Dec 31, 2025, Valbiotis SA's Other Current Assets amounts to 158k EUR.
What is Valbiotis SA's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
6%
Over the last year, the Other Current Assets growth was -36%. The average annual Other Current Assets growth rates for Valbiotis SA have been -14% over the past three years , 6% over the past five years .
